Payment overview · 2025
General Payments
$22,538.85
76 reported records · 18 companies
Healthcare provider profile · identity verified
Daniel Kwangwon Park, MD
Allopathic & Osteopathic Physicians|Orthopaedic Surgery · CHICAGO, IL · NPI 1073769162
Verified facts
What the public records show
CMS Open Payments records show Daniel Kwangwon Park, MD received $22,538.85 in general payments during 2025 across 76 reported records.
VB Spine LLC accounted for 67.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| VB Spine LLC | Unresolved — no canonical attribution shown | $15,144.24 | 67.2% | 4 | 2025 |
| Intrinsic Therapeutics | Unresolved — no canonical attribution shown | $3,000.00 | 13.3% | 10 | 2025 |
| Kuros Biosciences USA, Inc | Unresolved — no canonical attribution shown | $1,142.52 | 5.1% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $896.36 | 4.0% | 18 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $849.12 | 3.8% | 15 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$486.27 | 2.2% | 6 | 2025 |
| Highridge Medical LLC | Unresolved — no canonical attribution shown | $171.04 | 0.8% | 2 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $155.51 | 0.7% | 2 | 2025 |
| Cerapedics Inc. | Unresolved — no canonical attribution shown | $141.53 | 0.6% | 2 | 2025 |
| Centinel Spine, LLC | Unresolved — no canonical attribution shown | $124.47 | 0.6% | 1 | 2025 |
| Amplify Surgical, Inc. | Unresolved — no canonical attribution shown | $113.86 | 0.5% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $97.98 | 0.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.03 | 0.2% | 3 | 2025 |
| GetSet Surgical Inc | Unresolved — no canonical attribution shown | $52.00 | 0.2% | 1 | 2025 |
| Osteoremedies, LLC | Unresolved — no canonical attribution shown | $32.00 | 0.1% | 1 | 2025 |
| Augmedics Inc. | Unresolved — no canonical attribution shown | $29.07 | 0.1% | 2 | 2025 |
| Elevation Spine, Inc. | Unresolved — no canonical attribution shown | $25.92 | 0.1% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $21.93 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $18,606.43 | 13 |
| Food and Beverage | $3,270.95 | 61 |
| Travel and Lodging | $661.47 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUKON OCT SPINAL SYSTEM Normalized: yukon oct spinal system |
Device | Stryker Corporation, VB Spine LLC | $14,497.24 | 2 | 2025 |
Source payment records
|
|||||
| BARRICAID ACD (ANNULAR CLOSURE DEVICE) Normalized: barricaid acd annular closure device |
Device | Intrinsic Therapeutics | $3,000.00 | 10 | 2025 |
Source payment records
|
|||||
| MAGNETOS Normalized: magnetos |
Device | Kuros Biosciences USA, Inc | $1,142.52 | 4 | 2025 |
Source payment records
|
|||||
| EVEREST SPINAL SYSTEM Normalized: everest spinal system |
Device | Stryker Corporation, VB Spine LLC | $1,135.46 | 9 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $462.33 | 11 | 2025 |
Source payment records
|
|||||
| MAZOR X SYSTEM Normalized: mazor x system |
Device | Medtronic, Inc. | $303.30 | 3 | 2025 |
Source payment records
|
|||||
| ACP Normalized: acp |
Device | Globus Medical, Inc. | $174.50 | 1 | 2025 |
Source payment records
|
|||||
| COHERE Normalized: cohere |
Device | Globus Medical, Inc. | $174.50 | 1 | 2025 |
Source payment records
|
|||||
| MODULUS Normalized: modulus |
Device | Globus Medical, Inc. | $174.50 | 1 | 2025 |
Source payment records
|
|||||
| SIMPLIFY CERVICAL ARTIFICIAL DISC Normalized: simplify cervical artificial disc |
Device | Globus Medical, Inc. | $174.50 | 1 | 2025 |
Source payment records
|
|||||
| ALEUTIAN INTERBODY SYSTEMS Normalized: aleutian interbody systems |
Device | VB Spine LLC | $151.87 | 1 | 2025 |
Source payment records
|
|||||
| INDEPENDENCE Normalized: independence |
Device | Globus Medical, Inc. | $142.16 | 1 | 2025 |
Source payment records
|
|||||
| I-FACTOR PEPTIDE ENHANCED BONE GRAFT Normalized: i factor peptide enhanced bone graft |
Device | Cerapedics Inc. | $141.53 | 2 | 2025 |
Source payment records
|
|||||
| ROI-C Normalized: roi c |
Device | Highridge Medical LLC | $140.12 | 1 | 2025 |
Source payment records
|
|||||
| CATALYFT PL EXPANDABLE INTERBODY SYSTEM Normalized: catalyft pl expandable interbody system |
Device | Medtronic, Inc. | $135.99 | 1 | 2025 |
Source payment records
|
|||||
| PRODISC L Normalized: prodisc l |
Device | Centinel Spine, LLC | $124.47 | 1 | 2025 |
Source payment records
|
|||||
| VA-LCP Normalized: va lcp |
Device | DePuy Synthes Sales Inc. | $72.44 | 1 | 2025 |
Source payment records
|
|||||
| RAVINE Normalized: ravine |
Device | Stryker Corporation | $67.08 | 3 | 2025 |
Source payment records
|
|||||
| CORE Normalized: core |
Device | Stryker Corporation | $63.47 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.03 | 3 | 2025 |
Source payment records
|
|||||
| GoPLF! Posterior Lateral Fusion System Normalized: goplf posterior lateral fusion system |
Device | GetSet Surgical Inc | $52.00 | 1 | 2025 |
Source payment records
|
|||||
| SERRATO Normalized: serrato |
Device | Stryker Corporation | $48.50 | 2 | 2025 |
Source payment records
|
|||||
| Vyrsa V1 Normalized: vyrsa v1 |
Device | Globus Medical, Inc. | $46.26 | 1 | 2025 |
Source payment records
|
|||||
| SPINEJACK Normalized: spinejack |
Device | Stryker Corporation | $45.11 | 2 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $33.36 | 1 | 2025 |
Source payment records
|
|||||
| CHESAPEAKE STABILIZATION SYSTEM Normalized: chesapeake stabilization system |
Device | Stryker Corporation | $31.87 | 1 | 2025 |
Source payment records
|
|||||
| MOBI-C PLUG & FIT US Normalized: mobi c plug fit us |
Device | Highridge Medical LLC | $30.92 | 1 | 2025 |
Source payment records
|
|||||
| Xvision Normalized: xvision |
Device | Augmedics Inc. | $29.07 | 2 | 2025 |
Source payment records
|
|||||
| TRIALTIS Normalized: trialtis |
Device | DePuy Synthes Sales Inc. | $25.54 | 1 | 2025 |
Source payment records
|
|||||
| CANOPY Normalized: canopy |
Device | Globus Medical, Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| RELINE Normalized: reline |
Device | Globus Medical, Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| FLOSEAL Normalized: floseal |
Biological | Baxter Healthcare | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 68 | 45 |
| Methylprednisolone | Methylprednisolone | 65 | 54 |
| Gabapentin | Gabapentin | 63 | 31 |
| Tramadol Hcl | Tramadol Hcl | 60 | 49 |
| Methocarbamol | Methocarbamol | 52 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 35 |
| Celecoxib | Celecoxib | 22 | 13 |
| Mupirocin | Mupirocin | 18 | 18 |
| Pregabalin | Pregabalin | 15 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $22,538.85 · 76 records | VB Spine LLC | ACP, ALEUTIAN INTERBODY SYSTEMS, BARRICAID ACD (ANNULAR CLOSURE DEVICE), CANOPY, CATALYFT PL EXPANDABLE INTERBODY SYSTEM, CHESAPEAKE STABILIZATION SYSTEM, COHERE, CORE, EVENITY, EVEREST SPINAL SYSTEM, FLOSEAL, GoPLF! Posterior Lateral Fusion System, I-FACTOR PEPTIDE ENHANCED BONE GRAFT, INCEPTIV, INDEPENDENCE, KYPHON EXPRESS II KYPHOPAK TRAY, MAGNETOS, MAZOR X SYSTEM, MOBI-C PLUG & FIT US, MODULUS, PRODISC L, RAVINE, RELINE, ROI-C, SERRATO, SIMPLIFY CERVICAL ARTIFICIAL DISC, SPINEJACK, Senza, TRIALTIS, VA-LCP, Vyrsa V1, Xvision, YUKON OCT SPINAL SYSTEM | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error